NASDAQ · BYSI

BeyondSpring Inc.

$1.12 +$0.04 (+3.70%) 1D Market open

Key Metrics

$44.41M
Market cap
P/E · TTM
Revenue · TTM
−$7.64M
Net income
EPS · TTM $-0.19
Dividend yield
Free cash flow −$18.85M
Beta · 1Y 0.88
EBITDA · TTM −$8.19M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    From its Jul 2 high, the share price fell 42%.

    Peak close $1.87 on Jul 2; trough close $1.08 on Jul 23. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -42%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 19
    The stock moved -12.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 19
  • Mar 3
    The stock moved +13.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 3

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$44.41M
Enterprise value
Shares outstanding41.1M
52-wk range$0.99 – $2.44
Avg volume · 20D409.1K
Net cash
Book value / share$-0.86
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About BeyondSpring Inc.
IPO dateMar 9, 2017
Employees44

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 22.7% · 20.0%

Financial Health

Current ratio1.09
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$1.13M

Cash Flow · TTM

Operating CF −$18.85M
Capex $0
Free cash flow −$18.85M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings